InterCure (INCR) Stock Price, News & Analysis

Company Overview

InterCure Ltd. is an Israeli-based, vertically integrated cannabis company focused on the cultivation, manufacturing, research and distribution of medical cannabis products. Operating under licenses issued by the Israeli Ministry of Health, the company pursues a full value-chain approach from seed to shelf. InterCure’s activities encompass indoor and greenhouse cultivation, cannabinoid extraction, formulation of oils and tinctures, and compliance-driven packaging for both domestic and export markets.

The company’s portfolio is anchored by its controlled subsidiaries, including CannaKids, which develops pediatric-focused cannabis therapies, and Eybna Technologies, a research-driven unit specializing in terpene science. InterCure’s flagship cultivation facility near Ramla features automated climate controls and advanced irrigation systems designed to optimize cannabinoid and terpene profiles. Through partnerships with academic institutions and clinical centers, the company conducts ongoing trials targeting conditions such as chronic pain, neurological disorders and oncology-related symptoms.

InterCure serves patients and healthcare providers across Israel, and has established distribution channels in select European markets. Strategic alliances with licensed distributors in Germany, Italy and other jurisdictions enable the company to navigate complex regulatory frameworks while delivering standardized, GMP-compliant products. Looking ahead, InterCure is exploring opportunities in Latin America and pursuing additional export approvals in Asia-Pacific regions.

Founded in 2015 by industry entrepreneur Ido Kimchi, InterCure leverages a management team with deep expertise in agritech, pharmaceuticals and life-sciences research. The board includes seasoned executives in regulatory affairs, finance and international business development, underscoring the company’s commitment to rigorous quality controls and scalable operations. With a pipeline of next-generation formulations and a growing global footprint, InterCure aims to advance medical cannabis accessibility through science-driven innovation and strategic market expansion.

Key Stats

• Today's Range: $1.49 to $1.52
• 50-Day Range: $1.45 to $1.62
• 52-Week Range: $1.17 to $2.62
• Volume: 9,552 shs
• Average Volume: 25,915 shs
• Market Capitalization: $68.23 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

InterCure Stock Analysis - MarketRank™

InterCure scored higher than 13% of companies evaluated by MarketBeat, and ranked 881st out of 937 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for InterCure.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Book Value per Share Ratio

InterCure has a P/B Ratio of 0.64. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.06% of the float of InterCure has been sold short.

Short Interest Ratio / Days to Cover

InterCure has a short interest ratio ("days to cover") of 1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in InterCure has recently increased by 19.72%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

InterCure does not currently pay a dividend.

Dividend Growth

InterCure does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.06% of the float of InterCure has been sold short.

Short Interest Ratio / Days to Cover

InterCure has a short interest ratio ("days to cover") of 1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in InterCure has recently increased by 19.72%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 3.3 / 5
• News Sentiment: 1.87

News Sentiment

InterCure has a news sentiment score of 1.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.97 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for InterCure this week, compared to 0 articles on an average week.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, InterCure insiders have not sold or bought any company stock.

Percentage Held by Institutions

Only 8.34% of the stock of InterCure is held by institutions.

INCR Stock Analysis - Frequently Asked Questions

How have INCR shares performed this year?

InterCure's stock was trading at $1.59 at the beginning of 2025. Since then, INCR shares have decreased by 5.7% and is now trading at $1.50.

How do I buy shares of InterCure?

Shares of INCR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of InterCure own?

Based on aggregate information from My MarketBeat watchlists, some other companies that InterCure investors own include NVIDIA (NVDA), Meta Platforms (META), PayPal (PYPL), Advanced Micro Devices (AMD), Tesla (TSLA), Innovative Industrial Properties (IIPR) and AbbVie (ABBV).

Company Calendar

• Today: 7/16/2025
• Next Earnings (Estimated): 8/28/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED PRODUCTS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:INCR
• CIK: 1857030
• Web: www.intercure.co
• Phone: 972774605012
• Fax: N/A
• Employees: 350
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: 0.34
• Current Ratio: 1.73
• Quick Ratio: 1.18

Sales & Book Value

• Annual Sales: $64.55 million
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.36 per share
• Price / Book: 0.65

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: $70.64 million
• Optionable: Optionable
• Beta: 1.18